1,4-二羟基-8-氟-4-羰基喹啉-3-羧酸乙酯 | 71083-06-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,4-二羟基-8-氟-4-羰基喹啉-3-羧酸乙酯
• 中文别名: 8-氟-4-氧代-1,4-二氢喹啉-3-羧酸乙酯；1,4-二氢-8-氟-4-氧喹啉-3-羧酸乙酯
• 英文名称: ethyl 8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
• 英文别名: ethyl 8-fluoro-4-oxo-1H-quinoline-3-carboxylate
• CAS: 71083-06-2
• 化学式: C₁₂H₁₀FNO₃
• mdl: MFCD00052242
• 分子量: 235.215
• InChiKey: MPUYCZQHTGRPNE-UHFFFAOYSA-N

物化性质

• 熔点：
  217-219°C
• 沸点：
  341.8±42.0 °C(Predicted)
• 密度：
  1.318±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	Ethyl 8-fluoro-4-oxo-1 4-dihydroquinoline-3-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	71083-06-2

Section 1 - Chemical Product MSDS Name:Ethyl 8-fluoro-4-oxo-1 4-dihydroquinoline-3-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
71083-06-2	Ethyl 8-fluoro-4-oxo-1,4-dihydroquinol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 71083-06-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 217 - 219 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H10FNO3
Molecular Weight: 235

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 71083-06-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 71083-06-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 71083-06-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 71083-06-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,4-二羟基-8-氟-4-羰基喹啉-3-羧酸乙酯 在 nitronium tetrafluoborate 作用下， 以 乙腈 为溶剂， 反应 0.08h， 以84%的产率得到ethyl 8-fluoro-1,4-dihydro-5-nitro-4-oxoquinoline-3-carboxylate
  参考文献：
  名称：

  Regiocontrolled Nitration of 4-Quinolones at Ambient Conditions

  摘要：

  Regiocontrolled nitration of 4-quinolone, the highly privileged scaffold, has been developed at ambient conditions. The nitro group can selectively be introduced at diverse positions simply by tuning the reactivity of the moiety. Discrimination is being achieved through the selective functionalization of the free N-H group. The functional group has been screened theoretically with the help of Fukui function and local softness calculation. Theoretical predictions are synchronized well with the experimental findings. Finally, this nitration technique allows quick access to the structurally diverse 4-quinolones.

  DOI：

  10.1080/00397911.2015.1085576
• 作为产物：
  描述：

  2-氟苯胺 以 二苯醚 为溶剂， 反应 2.0h， 生成 1,4-二羟基-8-氟-4-羰基喹啉-3-羧酸乙酯
  参考文献：
  名称：

  羟基三萜酸和氟喹诺酮类新型抗菌和抗生物膜三唑缀合物的设计、半合成和分子对接

  摘要：

  以橄榄果渣 ( Olea europaea L.) 的天然产物分离五环三萜酸为原料，设计并半合成了一系列具有有效抗菌和抗生物膜活性的山楂酸 (MA) 和齐墩果酸 (OA) 类似物。这些缀合物是通过铜催化的叠氮化物-炔环加成 (CuAAC) 的最后一步合成的，在炔丙基化喹诺酮/氟喹诺酮 (QN/FQNs) 和 MA/OA 叠氮化物之间进行，以总体优异的收率获得新的三唑衍生物。后者的杂交体在体外筛选其对两种革兰氏阳性菌（金黄色葡萄球菌和粪肠球菌）和两种革兰氏阴性菌（金黄色葡萄球菌和粪肠球菌）的抗菌和抗生物膜活性。大肠杆菌和铜绿假单胞菌）。结果表明，一些山楂酸衍生物对所有测试菌株均表现出显着的活性，其 MIC 值在 3.25–30 μg mL -1范围内。此外，评估的化合物具有中度至显着的抗生物膜活性，对金黄色葡萄球菌生物膜形成的抑制百分比高达 68.75% 。使用合成化合物抗菌活性对接研究的分

  DOI：

  10.1039/d3nj02922k

文献信息

• Novel hybrids of metronidazole and quinolones: Synthesis, bioactive evaluation, cytotoxicity, preliminary antimicrobial mechanism and effect of metal ions on their transportation by human serum albumin
  作者：Sheng-Feng Cui、Li-Ping Peng、Hui-Zhen Zhang、Syed Rasheed、Kannekanti Vijaya Kumar、Cheng-He Zhou

  DOI：10.1016/j.ejmech.2014.08.063

  日期：2014.10

  A novel series of hybrids of metronidazole and quinolones as antimicrobial agents were designed and synthesized. Most prepared compounds exhibited good or even stronger antimicrobial activities in comparison with reference drugs. Furthermore, these highly active metronidazole–quinolone hybrids showed appropriate ranges of pKa, log P and aqueous solubility to pharmacokinetic behaviors and no obvious

  设计并合成了一系列新型的甲硝唑和喹诺酮类抗微生物剂。与参考药物相比，大多数制备的化合物表现出良好或什至更强的抗菌活性。此外，这些高活性甲硝唑-喹诺酮杂种对药代动力学表现出适当的pKa，log P和水溶解度范围，对A549和人肝细胞LO2细胞无明显毒性。它们与金属离子对HSA的竞争性相互作用表明，Mg 2+离子参与化合物7d -HSA缔合可能导致游离化合物7d的浓度增加。化合物7d的分子建模和实验研究 DNA提示可能的抗菌机制可能与生物活性分子和topo IV-DNA复合物之间的多个结合位点有关。
• 3-(Benzo[<i>d</i>]thiazol-2-yl)-4-aminoquinoline derivatives as novel scaffold topoisomerase I inhibitor <i>via</i> DNA intercalation: design, synthesis, and antitumor activities
  作者：Jing-Mei Yuan、Nan-Ying Chen、Hao-Ran Liao、Guo-Hai Zhang、Xiao-Juan Li、Zi-Yu Gu、Cheng-Xue Pan、Dong-Liang Mo、Gui-Fa Su

  DOI：10.1039/c9nj05846j

  日期：——

  Twenty-seven 3-(benzo[d]thiazol-2-yl)-4-aminoquinoline derivatives have been designed and synthesized as topoisomerase I inhibitors. The in vitro anti-proliferation evaluation against four human cancer cell lines (MGC-803, HepG-2, T24, and NCI-H460) and one normal cell line (HL-7702) indicated that most of them exhibited potent cytotoxicity. Among them, 5a was identified as the most promising candidate

  已经设计并合成了二十七个3-（苯并[ d ]噻唑-2-基）-4-氨基喹啉衍生物作为拓扑异构酶I抑制剂。在体外针对四种人类肿瘤细胞系（MGC-803，人肝癌HepG-2，T24，和NCI-H460）和一个正常细胞系的抗增殖评价（HL-7702）表示，其中大部分表现出强的细胞毒性。其中，5a被认为是最有前途的候选物，其IC 50值低至约2.20±0.14，并被选作进一步探索。光谱分析和琼脂糖凝胶电泳分析表明5a可以与DNA相互作用并强烈抑制拓扑异构酶I（Topo I）。进一步筛选化合物5b的Topo I活性，5c，5e，5f，5h，5i，5j，5l和5n表明一些化合物可能与5a具有完全不同的细胞毒性。分子建模研究证实5a采用独特的模式与DNA和Topo I相互作用。其他分子机理研究表明，用5a处理MGC-803细胞可诱导S期阻滞，上调促凋亡蛋白，下调抗凋亡蛋白，激活caspase-3，随后诱导
• A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy
  作者：Luca Agnetta、Michael Kauk、Maria Consuelo Alonso Canizal、Regina Messerer、Ulrike Holzgrabe、Carsten Hoffmann、Michael Decker

  DOI：10.1002/anie.201701524

  日期：2017.6.12

  synthetically incorporated a photoswitchable (photochromic) azobenzene moiety. We characterized the photophysical properties of this ligand called BQCAAI and investigated its applicability as a pharmacological tool compound with a set of FRET techniques at the M1 receptor. BQCAAI proved to be an unprecedented molecular tool; it is the first photoswitchable dualsteric ligand, and its activity can be regulated

  尽管总体上M受体和GPCR具有巨大的治疗意义，但对G蛋白偶联受体（GPCR）尤其是毒蕈碱型乙酰胆碱（mACh或M）受体激活的方式和时程的研究仍处于起步阶段。 。我们在本文中使用了双立体配体，该配体可以与直立的同时与神经递质，结合位点和变构的配体相互作用。我们合成了一个可光开关的（光致变色）偶氮苯部分。我们表征了这种称为BQCAAI的配体的光物理性质，并通过一套FRET技术在M 1处研究了其作为药理学工具化合物的适用性。受体。BQCAAI被证明是前所未有的分子工具。它是第一个可光转换的双空间配体，其活性可以受光调节。我们还应用了BQCCAI来研究几种受体激活过程的时间过程。
• 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
  申请人：Pharmacia & Upjohn Company

  公开号：US06093732A1

  公开（公告）日：2000-07-25

  The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula I ##STR1## These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.

  本发明提供了式I的4-羟基喹啉-3-甲酰胺和肼化合物。这些化合物可用于治疗或预防疱疹病毒感染，特别是人类巨细胞病毒感染。
• Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRβ and low blood–brain penetration
  作者：Baihua Hu、Ron Bernotas、Rayomand Unwalla、Michael Collini、Elaine Quinet、Irene Feingold、Annika Goos-Nilsson、Anna Wilhelmsson、Ponnal Nambi、Mark Evans、Jay Wrobel

  DOI：10.1016/j.bmcl.2009.11.062

  日期：2010.1

  A series of quinoline-3-carboxamide containing sulfones was prepared and found to have good binding affinity for LXRβ and moderate binding selectivity over LXRα. The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRβ over LXRα (LXRβ IC50 = 16 nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the

  制备了一系列包含喹啉-3-甲酰胺的砜，发现它们具有对LXRβ的良好结合亲和力和对LXRα的中等结合选择性。TPSA得分高的8-Cl喹啉类似物33对LXRβ的结合选择性超过LXRα的34倍（LXRβIC 50  = 16 nM），在THP巨噬细胞系中诱导ABCA1基因表达的活性良好，所需的弱效LXRαGal4功能测定和低血脑屏障穿透力在大鼠中。